Analysis and Perspectives

Mar 02, 2025

On September 29, 2023, FDA approved EXXUA, the ER gepirone hydrochloride tablets by Fabre-Kramer, for major depressive disorder treatment.

Mar 02, 2025

The major depressive disorder treatment market is expected to surge owing to the launch of novel therapies and key companies in the market.

Feb 15, 2025

In today's highly dynamic and fast-changing market, Competitive Intelligence plays a crucial role in making strategically smart decisions to outsmart the competition

Feb 12, 2025

Donanemab is a promising new Alzheimer’s disease treatment. Donanemab has the potential to rule the Alzheimer’s disease market.

Feb 12, 2025

Despite facing significant setbacks, companies such as Eli Lilly, BioVie, and others are developing effective Alzheimer's disease treatments.

Jan 06, 2025

Parkinson's disease treatment market to expand owing to novel therapies being developed by companies such as AZ, Cortexyme, and others.

Nov 29, 2024

The evolving landscape of NSCLC treatment presents significant market opportunities for pharmaceutical companies to secure their place.

Nov 20, 2024

Despite decades of research, treatment options are limited in the ARDS market. There are only a few treatments available in the ARDS market. The mainstay of management remains supportive care with mechanical ventilation. Other ARDS treatment options for patients include supplemental oxygen, prone positioning, the u...

Nov 20, 2024

As no approved drug in the ARDS market, uptake of emerging therapies is expected to be high. Currently, several assets are in the ARDS pipeline.

Nov 20, 2024

Acute respiratory distress syndrome (ARDS) prevalence is increasing drastically owing to certain factors such as pneumonia, COVID-19, sepsis,